keyword
MENU ▼
Read by QxMD icon Read
search

Cancer death dying chemotherapy

keyword
https://www.readbyqxmd.com/read/29024474/heart-failure-following-blood-cancer-therapy-in-pediatric-and-adult-populations
#1
Julie Franzon, Narelle M Berry, Shahid Ullah, Vincent L Versace, Alexandra L McCarthy, John Atherton, David Roder, Bogda Koczwara, Douglas Coghlan, Robyn A Clark
AIM: The link between chemotherapy treatment and cardiotoxicity is well established, particularly for adults with blood cancers. However, it is less clear for children. This analysis aimed to compare the trajectory and mortality of children and adults who received chemotherapy for blood cancers and were subsequently hospitalized for heart failure. METHODS: Linked data from the Queensland Cancer Registry, Death Registry and Hospital Administration records for initial chemotherapy and later heart failure were reviewed (1996-2009)...
October 12, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29020762/a-survival-analysis-of-gastric-or-colorectal-cancer-patients-treated-with-surgery-comparison-of-capital-and-a-non-capital-city
#2
Nam-Soo Hong, Kyeong Soo Lee, Sin Kam, Gyu Seog Choi, Oh Kyoung Kwon, Dong Hee Ryu, Sang Won Kim
Objectives: The objective of the present study was to compare prognosis of patients with gastric or colorectal cancer according to places where they received surgeries. Methods: The cancer patients underwent surgeries in sampled hospitals located in Daegu were matched 1:1 to the patients who visited sampled hospitals in Seoul using propensity score method. After the occurrences of death were examined, Kaplan-Meier method was used for survival analysis and the log-rank test was performed to compare the survival curves...
September 2017: Journal of Preventive Medicine and Public Health, Yebang Ŭihakhoe Chi
https://www.readbyqxmd.com/read/28975019/novel-therapies-in-platinum-refractory-metastatic-germ-cell-tumor-a-case-report-with-a-focus-on-a-pd-1-inhibitor
#3
Kah Poh Loh, Chunkit Fung
Testicular germ cell tumor (GCT) is the most common malignancy in young males between the ages of 15 to 35 years. Although the overall cure rate of GCTs approaches 95%, almost 25% of patients with distant metastases die from the cancer. Active investigations on novel treatment options for platinum-refractory GCTs include immunotherapies such as program-death 1 (PD-1)/program death-ligand 1 (PD-L1) inhibitors. In this case, we report a patient with metastatic GCTs who was treated with pembrolizumab, a PD-L1 inhibitor, in a phase II study after failing several lines of chemotherapy...
July 3, 2017: Rare Tumors
https://www.readbyqxmd.com/read/28967485/first-line-pembrolizumab-in-cisplatin-ineligible-patients-with-locally-advanced-and-unresectable-or-metastatic-urothelial-cancer-keynote-052-a-multicentre-single-arm-phase-2-study
#4
Arjun V Balar, Daniel Castellano, Peter H O'Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R Plimack, Noah M Hahn, Ronald de Wit, Lei Pang, Mary J Savage, Rodolfo F Perini, Stephen M Keefe, Dean Bajorin, Joaquim Bellmunt
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. We assessed the activity and safety of first-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer. METHODS: In this multicentre, single-arm, phase 2 study (KEYNOTE-052), cisplatin-ineligible patients with advanced urothelial cancer who had not been previously treated with systemic chemotherapy were recruited from 91 academic medical centres in 20 countries...
September 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28963112/disparities-in-the-intensity-of-end-of-life-care-for-children-with-cancer
#5
Emily E Johnston, Elysia Alvarez, Olga Saynina, Lee Sanders, Smita Bhatia, Lisa J Chamberlain
BACKGROUND: Many adult patients with cancer who know they are dying choose less intense care; additionally, high-intensity care is associated with worse caregiver outcomes. Little is known about intensity of end-of-life care in children with cancer. METHODS: By using the California Office of Statewide Health Planning and Development administrative database, we performed a population-based analysis of patients with cancer aged 0 to 21 who died between 2000 and 2011...
October 2017: Pediatrics
https://www.readbyqxmd.com/read/28954284/aggressive-end-of-life-care-for-metastatic-cancer-patients-younger-than-age-65-years
#6
Aaron D Falchook, Stacie B Dusetzina, Fang Tian, Ramsankar Basak, Nandini Selvam, Ronald C Chen
Background: Aggressive medical care at the end of life can be harmful to patients and families, but its prevalence in use among younger cancer patients is unknown. The goal of the study was to report on the use of aggressive care and hospice services for patients younger than age 65 years. Methods: Using the HealthCore Integrated Research Database, we analyzed patients who died between 2007 and 2014 with metastatic lung (n = 12 764), colorectal (n = 5207), breast (n = 5855), pancreatic (n = 3397), or prostate (n = 1508) cancer...
September 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28940952/real-world-uptake-safety-profile-and-outcomes-of-docetaxel-in-newly-diagnosed-metastatic-prostate-cancer
#7
Robert Rulach, Stephen McKay, Sam Neilson, Lillian White, Jan Wallace, Ross Carruthers, Carolynn Lamb, Almudena Cascales, Husam Marashi, Hilary Glen, Balaji Venugopal, Azmat Sadoyze, Norma Sidek, J Martin Russell, Abdulla Alhasso, David Dodds, Jennifer Laskey, Robert J Jones, Nicholas MacLeod
OBJECTIVES: To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone-naïve metastatic prostate cancer (mPC) in the first year of use outside of a clinical trial. SUBJECTS/PATIENTS AND METHODS: Patients in the West of Scotland Cancer Network (WoSCAN) with newly diagnosed mPC were identified from the regional multidisciplinary team (MDT) meetings and their treatment details were collected from electronic patient records. The rate of febrile neutropenia, hospitalisations, time to progression and overall survival were compared between those patients who received docetaxel and androgen deprivation therapy (ADT), or ADT alone using survival analysis...
September 20, 2017: BJU International
https://www.readbyqxmd.com/read/28900996/-clinicopathologic-characteristics-and-prognosis-of-gastric-hepatoid-adenocarcinoma
#8
Rongfei Zhao, Xinxin Wang, Xin Lan, Mingsen Li
OBJECTIVE: To investigate the clinicopathological characteristics, diagnosis, treatment and prognosis of gastric hepatoid adenocarcinoma(HAS). METHODS: Retrospective analysis of clinicopathological data of 24 cases with gastric HAS diagnosed by surgery and pathology in Chinese PLA General Hospital from January 2013 to May 2016 were carried out. All the patients underwent preoperative serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), endoscopy and imaging examination (CT or B-mode ultrasonography), and those with elevated AFP were excluded from liver cancer, cirrhosis, endodermal sinus tumor and other diseases...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900496/decreased-overall-and-cancer-specific-mortality-with-neoadjuvant-chemotherapy-in-locoregionally-advanced-nasopharyngeal-carcinoma-treated-by-intensity-modulated-radiotherapy-multivariate-competing-risk-analysis
#9
Jian Zhang, Hao Peng, Lei Chen, Wen-Fei Li, Yan-Ping Mao, Li-Zhi Liu, Li Tian, Ying Guo, Ying Sun, Jun Ma
Background: Value of neoadjuvant chemotherapy (NACT) is still controversial in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Based on competing risk analysis model, we aim at evaluating the efficacy of NACT in decreasing cancer-specific mortality for LA-NPC (except T3-4N0) treated by intensity-modulated radiotherapy (IMRT). Methods: Data on 957 patients with LA-NPC were retrospectively reviewed. The cumulative incidence of cancer-specific and non-cancer-specific (competing) mortality was determined by univariate and multivariate competing risk analysis...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28882536/gemcitabine-and-docetaxel-versus-doxorubicin-as-first-line-treatment-in-previously-untreated-advanced-unresectable-or-metastatic-soft-tissue-sarcomas-geddis-a-randomised-controlled-phase-3-trial
#10
RANDOMIZED CONTROLLED TRIAL
Beatrice Seddon, Sandra J Strauss, Jeremy Whelan, Michael Leahy, Penella J Woll, Fiona Cowie, Christian Rothermundt, Zoe Wood, Charlotte Benson, Nasim Ali, Maria Marples, Gareth J Veal, David Jamieson, Katja Küver, Roberto Tirabosco, Sharon Forsyth, Stephen Nash, Hakim-Moulay Dehbi, Sandy Beare
BACKGROUND: For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma. METHODS: The GeDDiS trial was a randomised controlled phase 3 trial done in 24 UK hospitals and one Swiss Group for Clinical Cancer Research (SAKK) hospital. Eligible patients had histologically confirmed locally advanced or metastatic soft-tissue sarcoma of Trojani grade 2 or 3, disease progression before enrolment, and no previous chemotherapy for sarcoma or previous doxorubicin for any cancer...
October 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28874892/treatment-patterns-and-trends-in-patients-dying-of-prostate-cancer-in-quebec-a-population-based-study
#11
A Dragomir, J Rocha, M Vanhuyse, F L Cury, W Kassouf, J Hu, A G Aprikian
INTRODUCTION: Since just after the year 2000 in Quebec, the management of metastatic castration-resistant prostate cancer (mcrpc) has evolved considerably, with the inclusion of docetaxel-based chemotherapy, bone-targeted therapies (zoledronic acid and denosumab), and more recently, abiraterone, enzalutamide, and cabazitaxel for docetaxel-refractory patients. In the present study, we aimed to analyze contemporary mcrpc management patterns and therapy utilization trends in Quebec. METHODS: The study cohort consisted of patients dying of prostate cancer (pca) between January 2001 and December 2013, selected from Quebec public health care insurance databases...
August 2017: Current Oncology
https://www.readbyqxmd.com/read/28873267/administration-of-adjuvant-chemotherapy-in-older-patients-with-stage-iii-colon-cancer-an-observational-study
#12
C B M van den Broek, C C E M Puylaert, A J Breugom, E Bastiaannet, A J M de Craen, C J H van de Velde, G-J Liefers, J E A Portielje
AIM: According to established guidelines, patients with Stage III colon cancer should receive adjuvant chemotherapy. However, a significant proportion do not. This study assessed factors associated with the administration of adjuvant chemotherapy and causes of death. METHODS: Patients with Stage III colon cancer who underwent surgery between 2000 and 2009 were selected from two hospitals in the Netherlands. Patient characteristics including comorbidities and treatment preferences, tumour characteristics and follow-up were extracted from the medical records...
October 2017: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/28870611/safety-and-activity-of-microrna-loaded-minicells-in-patients-with-recurrent-malignant-pleural-mesothelioma-a-first-in-man-phase-1-open-label-dose-escalation-study
#13
MULTICENTER STUDY
Nico van Zandwijk, Nick Pavlakis, Steven C Kao, Anthony Linton, Michael J Boyer, Stephen Clarke, Yennie Huynh, Agata Chrzanowska, Michael J Fulham, Dale L Bailey, Wendy A Cooper, Leonard Kritharides, Lloyd Ridley, Scott T Pattison, Jennifer MacDiarmid, Himanshu Brahmbhatt, Glen Reid
BACKGROUND: TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss of the miR-15 and miR-16 family miRNAs, which is associated with unsuppressed tumour growth in preclinical models of malignant pleural mesothelioma. We aimed to assess the safety, optimal dosing, and activity of TargomiRs in patients with malignant pleural mesothelioma. METHODS: In this first-in-man, open-label, dose-escalation phase 1 trial at three major cancer centres in Sydney (NSW, Australia), we recruited adults (aged ≥18 years) with a confirmed diagnosis of malignant pleural mesothelioma, measurable disease, radiological signs of progression after previous chemotherapy, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 3 months or more, immunohistochemical evidence of tumour EGFR expression, and adequate bone marrow, liver, and renal function...
October 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28851760/tumor-lysis-syndrome-in-chronic-lymphocytic-leukemia-with-novel-targeted-agents
#14
Bruce D Cheson, Sari Heitner Enschede, Elisa Cerri, Monali Desai, Jalaja Potluri, Nicole Lamanna, Constantine Tam
Tumor lysis syndrome (TLS) is an uncommon but potentially life-threatening complication associated with the treatment of some cancers. If left untreated, TLS may result in acute renal failure, cardiac dysrhythmia, neurologic complications, seizures, or death. Tumor lysis syndrome is most commonly observed in patients with hematologic malignancies with a high proliferation rate undergoing treatment with very effective therapies. In chronic lymphocytic leukemia (CLL), historically, TLS has been observed less often, owing to a low proliferation rate and slow response to chemotherapy...
August 29, 2017: Oncologist
https://www.readbyqxmd.com/read/28845536/prevalence-and-determinants-of-end-of-life-chemotherapy-use-in-patients-with-metastatic-breast-cancer
#15
Aju Mathew, Tala Achkar, Shira Abberbock, Gurprataap S Sandhu, Mini Elizabeth Jacob, Vipin Das Villgran, Margaret Q Rosenzweig, Shannon Puhalla, Adam M Brufsky
Cessation of chemotherapy in the last few weeks of life could be an important quality-of-care benchmark. Proportion of metastatic breast cancer patients who receive end-of-life chemotherapy is not well described. We aimed to determine the prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. A retrospective cohort study using a prospectively collated database of patients with metastatic breast cancer who died between January 1, 2010, and September 30, 2014, was conducted...
August 28, 2017: Breast Journal
https://www.readbyqxmd.com/read/28844816/guadecitabine-sgi-110-in-treatment-naive-patients-with-acute-myeloid-leukaemia-phase-2-results-from-a-multicentre-randomised-phase-1-2-trial
#16
RANDOMIZED CONTROLLED TRIAL
Hagop M Kantarjian, Gail J Roboz, Patricia L Kropf, Karen W L Yee, Casey L O'Connell, Raoul Tibes, Katherine J Walsh, Nikolai A Podoltsev, Elizabeth A Griffiths, Elias Jabbour, Guillermo Garcia-Manero, David Rizzieri, Wendy Stock, Michael R Savona, Todd L Rosenblat, Jesus G Berdeja, Farhad Ravandi, Edwin P Rock, Yong Hao, Mohammad Azab, Jean-Pierre J Issa
BACKGROUND: The hypomethylating drugs azacitidine and decitabine have shown efficacy in myelodysplastic syndromes and acute myeloid leukaemia, but complete tumour responses are infrequent and of short duration, possibly because of the short half-lives and suboptimal bone marrow exposure of the drugs. Guadecitabine, a next-generation hypomethylating drug, has a longer half-life and exposure than its active metabolite decitabine. A phase 1 study established 60 mg/m(2) guadecitabine for 5 days as an effective treatment schedule...
October 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28842111/sex-disparities-after-induction-chemoradiotherapy-and-esophagogastrectomy-for-esophageal-cancer
#17
Phillip G Rowse, Dawn E Jaroszewski, Mathew Thomas, Kristi Harold, William S Harmsen, K Robert Shen
BACKGROUND: The impact of sex on the outcomes of treatment for locally advanced esophageal carcinoma is unclear. This study analyzed the impact of sex on response to neoadjuvant chemoradiotherapy (nCRT), tumor recurrence, and survival. METHODS: From January 1990 through December 2013, female patients who received nCRT followed by esophagogastrectomy at 3 affiliated centers were compared with control male patients based on age, pretreatment clinical stage, histologic type, and surgical era...
October 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28838265/ninety-day-post-operative-morbidity-and-mortality-using-the-national-cancer-institute-s-common-terminology-criteria-for-adverse-events-better-describe-post-operative-outcome-after-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#18
Mohammad Alyami, Bradford J Kim, Laurent Villeneuve, Delphine Vaudoyer, Vahan Képénékian, Naoual Bakrin, Francois-Noel Gilly, Eddy Cotte, Olivier Glehen, Guillaume Passot
BACKGROUND: The post-operative morbidity and mortality after CRS-HIPEC has been widely evaluated. However, there is a major discrepancy between rates reported due to different metrics and time of analysis used. OBJECTIVE: To evaluate the legitimacy of 90-day morbidity and mortality based on the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 classification as criteria of quality for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)...
August 24, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28830717/mid-radiotherapy-pet-ct-for-prognostication-and-detection-of-early-progression-in-patients-with-stage-iii-non-small-cell-lung-cancer
#19
Michael F Gensheimer, Julian C Hong, Christine Chang-Halpenny, Hui Zhu, Neville C W Eclov, Jacqueline To, James D Murphy, Heather A Wakelee, Joel W Neal, Quynh-Thu Le, Wendy Y Hara, Andrew Quon, Peter G Maxim, Edward E Graves, Michael R Olson, Maximilian Diehn, Billy W Loo
BACKGROUND AND PURPOSE: Pre- and mid-radiotherapy FDG-PET metrics have been proposed as biomarkers of recurrence and survival in patients treated for stage III non-small cell lung cancer. We evaluated these metrics in patients treated with definitive radiation therapy (RT). We also evaluated outcomes after progression on mid-radiotherapy PET/CT. MATERIAL AND METHODS: Seventy-seven patients treated with RT with or without chemotherapy were included in this retrospective study...
August 19, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28797070/methyl-pyruvate-protects-a-normal-lung-fibroblast-cell-line-from-irinotecan-induced-cell-death-potential-use-as-adjunctive-to-chemotherapy
#20
Bernice Monchusi, Monde Ntwasa
The Warburg Effect, characterized by increased rate of glycolysis even under normoxic conditions, is one of the hallmarks of cancer. Relatively lower oxidative phosphorylation (OXPHOS) is also a characteristic feature in cancer cells. We hypothesized that interference with this phenomenon, by introducing exogenous pyruvate, would upset this cancer phenotype and boost the energy requirements of normal cells. We find that methyl pyruvate protects irinotecan-treated normal lung fibroblast cell line (MRC-5) probably by turning off the p53/p21 axis of the apoptotic pathways...
2017: PloS One
keyword
keyword
67076
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"